• Stromal OPN anchors leukemia cells in pro-dormancy BM niches. Inhibiting this interaction leads dormant cells to proliferate, sensitizing them to chemotherapy.
Introduction
Acute lymphoblastic leukemia (ALL) in adults initially responds well to induction chemotherapy, with greater than 80% of patients attaining a complete remission (CR).
Unfortunately, most initial CRs are short lived and overall survival is only 30-40% for adults who are diagnosed before age 60 1 . Although outcomes in the pediatric population are better, there are still a significant number of patients who suffer from relapsed or refractory disease 2 .
Relapses in both populations are believed to be the outgrowth of MRD that is not completely eliminated by chemotherapy. Indeed, it has been demonstrated that patients with the lowest levels of detectable MRD at CR have the best prognosis and least likelihood of relapse 2 .
Strategies to overcome resistance and reduce MRD may therefore have the potential to increase overall survival.
Anti-apoptotic signals from the host tissue microenvironment are increasingly recognized as important mechanisms of malignant cell survival against chemotherapy. Our previous work using the Nalm-6 model of ALL has shown that the BM microenvironment plays a critical role in disease spread and in the dysregulation of normal hematopoiesis that occurs during leukemic growth 3, 4 . To metastasize and outcompete native BM cells, leukemic cells co-opt normal signaling mechanisms within hematopoietic stem cell (HSC) niches. At least two distinct HSC niches, one perivascular and one endosteal (or bony) exist in the BM 5 . In the basal state, interactions between HSCs and specific cells and molecules within these niches modulate HSC transit and self-renewal 6, 7 . While the anatomic and molecular distinction between these niches is controversial, evidence suggests that the endosteal niche maintains a population of quiescent
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Stromal cell-derived factors, including cytokines and extracellular matrix proteins (ECMs), play a significant role in niche regulation of the benign HSC population. One important protein expressed by endosteal osteoblasts and implicated in HSC migration and self-renewal is OPN 5, [10] [11] [12] [13] [14] . Extracellular OPN is a multidomain secreted glycoprotein that can function as a soluble cytokine/chemokine as well as an adhesive component of the ECM. It is bound by multiple cell surface receptors including CD44, α V β 3 , (α 4, α 9, α 5 )β 1 , and α 4 β 7 integrins [15] [16] [17] [18] . OPN expression is necessary for proper trans-marrow migration and lodgment of HSCs at the endosteal surface, a process mediated by α 4 β 1 and α 9 β 1 integrins 19, 20 . Furthermore, HSC engagement with OPN constrains HSC pool size, and there is an increased number of cycling progenitors in the marrow and peripheral blood of OPN-/-mice 20, 21 .
The role of OPN has been extensively investigated in solid malignancies, with multiple studies showing that OPN positively regulates tumor cell proliferation and metastasis 16, [22] [23] [24] [25] . Despite the well-defined functions for OPN in solid tumor and benign HSC biology, there is little data regarding OPN and leukemia. A limited number of studies of human AML patients demonstrate that increased BM transcript and serum OPN levels correlate with decreased overall survival, suggesting a function for OPN in leukemia progression 26, 27 . Using murine xenograft models in combination with highly sensitive in vivo microscopy of the calvarial BM, we set out to investigate the role of OPN in ALL, and in particular, the persistence of MRD after chemotherapy.
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Materials and Methods
Cell lines and culture. The GFP expressing clone of Nalm-6 was generated and cultured as previously described 28 .
In vitro adhesion assay. Recombinant human OPN was thrombin-cleaved and plates coated at 20 μg/mL. Nalm-6-GFP or primary ALL cells were resuspended in adhesion buffer (1μM PMA and 2mM MnCl 2 ) and allowed to adhere for 2 hours.
In vivo OPN neutralization. SCID mice were injected via t.v. with 1 mg/kg anti-mouse and 2 mg/kg anti-human OPN or isotype control (Day 0). 24 hours post-injection, mice were engrafted with Nalm-6-GFP. Mice were retreated on Day 7 and Day 14 and sacrificed on Day 21.
Intravital microscopy. Imaging was performed as previously described 28 .
In vivo Ara-C MRD studies. Mice were engrafted with DiR labeled Nalm-6-GFP on Day 0.
On Day 10, mice were injected via t.v. with 1 mg/kg anti-mouse and 2 mg/kg anti-human OPN or isotype control. Mice were treated with Ara-C (500mg/m 2 I.P.) on Days 10-14 and 24-28 and imaged on Day 35.
All animal experiments were performed following guidelines approved by the Institutional Animal Care and Use Committee at the University of Chicago -protocol #71675.
Detailed methods are provided in Supplemental Materials.
Results
Human ALL blasts highly express OPN when localized to the endosteal niche OPN expression in ALL BM has not previously been described. We therefore performed OPN immunohistochemistry (IHC) on diagnostic BM biopsies from 6 patients with precursor-B ALL.
BM biopsies from lymphoma patients with no pathological evidence of BM infiltration served as controls. OPN expression was detected in leukemia cells from all 6 ALL patients, suggesting that OPN upregulation is a common event in ALL. Furthermore, as shown in Figure 1A , a gradient of OPN expression was detected in several leukemic marrows, with OPN-expressing blasts localized near trabecular bone surfaces in areas of high endosteal matrix OPN deposition. This result suggests that OPN levels are elevated in the endosteal niche in ALL, and that this niche may specifically recruit OPN-expressing blasts or expresses factors that induce OPN expression in adjacent lymphoblasts.
Primary ALL cells express OPN receptors and adhere to thrombin-cleaved OPN in vitro
Whether ALL cells can interact with extracellular OPN has not previously been tested. Using flow cytometry, we analyzed a set of primary human BM B-ALL cells for surface expression of known OPN receptors 18 . As shown in Figure 1B , hALL express multiple OPN cell surface receptors, including the α 4 β 1, α 5 β 1, and α 9 β 1 integrins and CD44. α 4 and α 5 integrins appeared to have the highest cell surface expression, while α 9 β 1 integrin and CD44 expression were relatively weak. Figure 1C ). Interestingly, 2/3 of the OPN non-adherent samples were from patients presenting with high peripheral white blood cell counts.
Dormant primary leukemia cells localize to areas of high OPN expression in vivo
It has been reported that BM OPN induces HSC quiescence by serving as a chemotactic factor that recruits and anchors HSCs to the pro-dormancy endosteal microenvironment 20 . Given our observation that OPN expression was elevated in endosteal regions of human ALL BM, we hypothesized that OPN might similarly regulate leukemic blast dormancy in these niches. To test this hypothesis, we first investigated whether quiescent leukemic cells preferentially co-localize with areas of high OPN expression in the tumor microenvironment. BM blasts from a patient with pre-B ALL were purified by FACS and labeled with a fluorescent membrane dye that is retained in dormant, non-cycling cells but diluted to undetectable levels in proliferating cells 29 .
Cells were then engrafted via tail vein into NSG mice.
To determine the 3-dimensional relationship between leukemic cells and the specific anatomic locations in the marrow where extracellular OPN is expressed, we utilized intra-vital confocal microscopy to image the calvarial BM of mice. This approach allows us to detect soluble OPN, which is typically lost during the processing of tissue sections. Leukemic mice were injected with murine/human cross-reactive fluorescence-labeled anti-OPN antibodies approximately 20 hours prior to imaging on post-engraftment day 42. As shown in Figure 1D , extracellular OPN signal is detected in the NSG mice but not OPN null mice or NSG mice injected with AF647-labeled isotype control antibody (Supplemental Figure 1) , confirming the specificity of the Figure 1D ). Dye-retaining cells were also noted to be intensely bright, suggesting they had undergone very few divisions in vivo (Supplemental Figure 2) . These data suggested the possibility of a functional connection between dormant leukemic cells and extracellular OPN. To validate Nalm-6 as a model for our investigations, we first analyzed their expression of OPN cell surface receptors by flow cytometry. Similar to primary ALL, Nalm-6 express the α 4 β 1,
For personal use only. on April 19, 2017 . by guest www.bloodjournal.org From α 5 β 1, and α 9 β 1 integrins, although they do not express CD44 (Figure 2A ). Neither Nalm-6 nor primary ALL express the α v or β 7 integrins. To test whether Nalm-6 cells can functionally interact with OPN, we performed in vitro adhesion assays to OPN using fibronectin, an α 4 β 1 ligand, as positive control. Nalm-6 strongly adhered to thrombin-cleaved OPN, but showed weak adhesion to full-length OPN ( Figure 2B ). Pre-treatment with an OPN neutralizing antibody specifically inhibited Nalm-6 adhesion to thrombin-cleaved OPN but not to fibronectin ( Figure 2C ).
It has recently been reported that thrombin cleavage of OPN exposes a cryptic integrin binding epitope on the N-terminal cleavage fragment that is recognized by α 4 β 1 and α 9 β 1 19, 20 . To further define the receptors involved in OPN adhesion, Nalm-6 cells were pre-treated with α 4 β 1 neutralizing antibodies. VLA-4 (α 4 β 1 ) blockade almost entirely abrogated adhesion to thrombincleaved OPN, suggesting that Nalm-6 binding to OPN is mediated principally by VLA-4 ( Figure   2D ).
Our data from immunohistochemical staining of human ALL BM biopsies demonstrated that lymphoblasts, like BM stromal cells, can express OPN. Investigations of solid tumor and myeloma models have shown that these malignant cells both produce and secrete OPN 16, 17, 27 We therefore tested whether Nalm-6 synthesize and secrete OPN in vitro. As seen in Figure 2 , Nalm-6 express OPN mRNA transcripts ( Figure 2E ) and secrete OPN protein into culture media ( Figure 2F ). Multiple additional ALL cell lines and primary ALL cells were also demonstrated to express OPN mRNA transcripts (Supplemental Figure 3) . These results suggested that leukemia itself could be a source of ECM OPN in the BM microenvironment in vivo.
The leukemia BM microenvironment contains increased levels of both leukemia-and hostderived OPN
Having shown that Nalm-6 express OPN in vitro, we next tested whether Nalm-6 express and secrete OPN in vivo, and whether leukemic engraftment affects host OPN production. Using primers specific to human OPN mRNA, we performed real-time PCR analysis on control unengrafted mouse and Nalm-6 leukemic mouse BM. As shown in Figure 3A , human OPN transcripts are readily detected in the leukemic BM, demonstrating that Nalm-6 continue to express OPN while resident within the marrow. In addition, IHC analysis demonstrates blastspecific OPN expression in the tumor microenvironment ( Figure 3B ). Interestingly, similar to our findings in primary ALL BM, this expression is highest in leukemic cells that are near the OPN-rich endosteum, suggesting that Nalm-6 OPN production may itself be regulated by the niche.
To determine whether OPN-producing leukemic cells secrete OPN into the tumor microenvironment, we performed human-specific OPN ELISA analysis on BM serum from leukemic vs. control mice. Human OPN was detected in the BM sera of tumor-engrafted mice ( Figure 3C and Supplemental Figure 4 ), confirming that leukemic blasts can secrete OPN into the BM microenvironment in vivo. To establish whether leukemia engraftment affects host stromal production of OPN, we next performed quantitative PCR analysis of murine OPN mRNA levels in leukemic and control mouse femurs. Forty days post Nalm-6-GFP engraftment, murine OPN transcripts are significantly increased in leukemic BM ( Figure 3D ). Taken together, our data suggest that increased OPN production in the tumor microenvironment is derived from both invading tumor and reactive host stroma. In addition, the enriched expression of OPN by blasts localized to the endosteum suggests that tumor-stroma cross-talk within this niche provides a positive feedback loop for OPN expression.
We next utilized in vivo confocal microsocopy to determine the relationship of OPN expression to leukemic growth in the BM. As shown in Figure 3E -H, OPN signal is intense and highest in the ECM adjacent to areas of significant tumor burden. These data confirm that OPN expression is increased in the tumor microenvironment and that it is highly expressed in specific niches that are invaded by leukemia.
Dormant but not proliferative Nalm-6 cells localize to areas of high OPN expression in vivo
We next performed studies to determine whether quiescent Nalm-6 cells, like dormant primary ALL cells, co-localized with ECM OPN in vivo. By engineering Nalm-6 to constitutively express GFP, we were also able to determine whether proliferating cells that had diluted fluorescent membrane dye label to undetectable levels co-localized with or were distant from extracellular OPN. 42 days after engraftment of dye labeled Nalm-6-GFP, mice were injected with AF647 labeled anti-OPN antibodies and the calvarial BM was imaged as previously described. As shown in Figure 4A and B, the majority of dormant, dye-retaining cells colocalize with areas of high OPN expression in the marrow, while few proliferating cells (GFP+, dye negative) co-localize with OPN. These data suggested the possibility of a functional connection between dormant leukemic cells and BM OPN.
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Neutralization of OPN in vivo induces leukemia cell cycle entry and increases disease burden
To further test the relationship between OPN and tumor dormancy, we developed an in vivo OPN neutralization strategy. Because our data suggested that tumor and host both contribute to the increased OPN levels in leukemic BM, we used a cocktail of anti-mouse and anti-human OPN neutralizing antibodies to inhibit Nalm-6 interaction with extracellular OPN. As shown in Figure   5A , both neutralizing antibodies effectively reduce Nalm-6 binding to murine or human thrombin-cleaved OPN in vitro and each display some degree of cross-species neutralization.
Because OPN is a chemotactic cytokine, we also assessed whether treatment of mice with the neutralizing antibody cocktail could inhibit leukemia cell homing to the BM. Treatment of mice with the neutralizing cocktail prior to leukemia cell engraftment did not affect Nalm-6-GFP BM homing ( Figure 5B ).
Based on these data, we then undertook long-term studies of in vivo OPN blockade in leukemic mice. Mice were injected with the OPN neutralizing antibody or isotype control antibody following the schedule outlined in Figure 5C . 21 days post tumor engraftment, mice were sacrificed and femur and iliac crest BM harvested for flow cytometric analysis of GFP+ leukemia cell burden. In marked contrast to the anti-proliferative effect of OPN inhibition that has been observed in solid tumor models 16, [23] [24] [25] 32 , OPN neutralization in our ALL model led to an approximately 2-fold increase in tumor burden ( Figure 5D and E). Moreover, OPN neutralization increased the Ki-67 proliferative index in leukemic cells, suggesting that interaction with OPN in the BM microenvironment leads to cell cycle withdrawal in leukemic blasts ( Figure 5F ).
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Multiple groups have demonstrated an in vivo role for OPN in the chemoattraction of macrophages 33, 34 . To confirm that the observed increase in tumor burden was not the result of failure to recruit macrophages into the tumor bed, we stained BM aspirates from control and OPN neutralized mice for the murine macrophage marker, F4/80 antigen. Flow cytometric analysis showed that OPN neutralization did not affect macrophage residency in the marrow ( Figure 5G ).
To test whether leukemic cell engagement with OPN directly altered cell proliferation, Nalm-6 cells were incubated with either tcOPN or OPN neutralizing Abs and a 72hr MTT proliferation assay performed ( Figure 5H ). Neither treatment had a direct effect on cell proliferation. We next examined whether blockade of the α 4 β 1 receptor, which abrogated Nalm-6 binding to OPN in vitro, would also increase Nalm-6 tumor burden. Consistent with the previously defined role of integrins in activating cell cycle progression, blockade of Nalm-6 VLA-4 with anti-human VLA-4 blocking antibodies decreased tumor burden in treated vs. control mice (data not shown).
These data suggest that the dormancy-inducing effect of ECM OPN on Nalm-6 is indirect and likely related to its role in anchoring Nalm-6 within specific microenvironments where additional factors act to induce cell cycle arrest.
OPN neutralization synergizes with Ara-C based chemotherapy to reduce MRD
Current frontline therapies for ALL revolve around cytotoxic agents that target actively cycling cells. MRD that persists after chemotherapy, however, can lead to disease relapse, and the degree of MRD is an independent prognostic indicator in humans 2 . A contributing factor to MRD may be the inability of cytotoxic agents to eradicate non-cycling, or dormant cells. Our
For personal use only. on April 19, 2017 . by guest www.bloodjournal.org From results suggested that a significant number of leukemic blasts enter a dormant state in the BM via their interaction with extracellular OPN. We therefore wished to test whether OPN neutralization could sensitize leukemic blasts to an Ara-C-based chemotherapy regimen and thereby reduce MRD. To test this hypothesis, we developed an Ara-C dosing strategy involving multiple rounds of chemotherapy designed to eliminate all but the most highly resistant disease ( Figure 6A ). MRD after treatment could only be detected by high resolution imaging of the calvarial BM yet produced disease relapse measurable by flow cytometry in mice over time, thus modeling disease recurrence in patients who appear to have initial cure. Mice were given chemotherapy with or without OPN neutralization as pre-treatment. At the end of therapy, we imaged the calvarial BM to sensitively identify rare tumor cells. As demonstrated in Figure 6B and C, the combination of a single OPN neutralization treatment prior to Ara-C significantly reduces MRD compared to Ara-C treatment alone.
Discussion
Clinical studies have demonstrated that even when MRD is not completely eradicated, decreases in MRD burden correlate with significant improvements in overall survival 2, 35, 36 . New methods to diminish post-therapy MRD are therefore critically important. Given that quiescent cancer cells are resistant to standard cytotoxic therapies, one approach to improve chemotherapy efficacy and reduce MRD would be to force quiescent leukemic cells into active phases of the cell cycle.
The BM microenvironment contains niches that regulate the dormancy of HSCs and shelter them from chemotherapeutic insult. Moreover, several HSC niche components, including OPN, SDF- [11] [12] [13] [14] 20, 21, 37 . We have previously demonstrated that leukemic cells hijack normal HSC-niche homing signals to metastasize within the BM, and that leukemia engraftment in HSC niches induces significant alterations in the niche that favor leukemia cell growth over HSC survival 3, 28 . How unique niches regulate leukemia cell proliferation or dormancy is not, however, well understood. Here we provide evidence that specific OPN+ niches within the marrow function to reversibly inhibit the proliferation of leukemic blasts, and that blocking this interaction increases the efficacy of cytotoxic chemotherapy aimed at actively cycling cells. A model for this relationship is presented in Figure 7 . These data provide the first proof-of-principle that specific BM niches can function to maintain leukemia cell dormancy.
While OPN adherence is a key mechanism to retain leukemic cells in pro-dormancy niches, ECM OPN does not appear to directly induce quiescence in blasts. Our data suggest that OPN exerts its effects in the Nalm-6 ALL model via engagement of α 4 β 1 integrin receptors, as inhibition of α 4 β 1 (VLA-4) completely abrogated Nalm-6 binding to OPN in vitro. VLA-4, however, interacts with multiple binding partners present in the BM microenvironment, including VCAM-1 and fibronectin, and activation of integrin receptors by these ligands typically stimulates cell cycle progression 38 . Indeed, in vivo VLA-4 blockade in Nalm-6 ALL mice inhibits rather than promotes ALL proliferation 39 . These findings suggest that OPNinduced quiescence is due to its critical role as an anchor for leukemic cells within pro-dormancy niches, where other factors in the local microenvironment then promote cell cycle arrest. Such secondary factors might include hypoxia, specific cytokines, direct interaction with stromal cells or, potentially, a complex combination of these metabolic, stromal and cytokine cues.
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In contrast to the paucity of research on OPN and leukemia, there is a well-defined association between OPN and solid tumor progression, with multiple reports linking OPN expression to tumor growth and metastasis in breast, gastrointestinal, prostate and lung cancers, among others 16, [22] [23] [24] [25] . In contrast to our findings, these studies have shown OPN to promote tumorigenesis, in some cases through autocrine signaling mechanisms 32 . One potential explanation for these dissimilar results is that leukemic cells, in contrast to solid tumors, bind poorly to full-length OPN. Rather, ALL binds strongly to thrombin-cleaved OPN, the predominant form of OPN in the BM of mice and humans 20 . Cleavage of OPN by thrombin reveals a cryptic epitope that is recognized specifically by the integrin receptors α 4 β 1 and α 9 β 1 that are preferentially expressed by leukocytes and HSCs 20 . This suggests that control of tumor cell dormancy is a novel function of OPN that is contextual to the BM microenvironment.
Another intriguing finding from our study is that OPN expression in the niche is influenced by dynamic cross-talk between leukemia and host. Our data reveal that the niche is "remodeled" during leukemia progression as host and tumor react to each other. In response to leukemic infiltration, host OPN production increases. At the same time, leukemia cells in OPN-rich BM regions secrete high levels of OPN that are incorporated locally into the ECM. These results suggest a positive feedback loop in which tumor-derived OPN can expand the quiescent niche and reinforce the dormant phenotype.
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Our investigation of OPN expression in primary human pre-B ALL samples revealed blastspecific OPN expression and expression of OPN cell surface receptors in all subjects analyzed, suggesting that OPN expression is a common feature of human ALL. The ability of primary blasts to adhere to OPN in vitro, however, was highly variable. Determining whether the capacity of blasts to adhere to OPN correlates with clinical outcomes in ALL is thus an interesting subject for future investigations.
Before a therapy based on OPN neutralization can be translated to the clinic, potential toxic side effects on benign HSCs need to be assessed to determine the impact of combined OPN blockade and chemotherapy on the viability and function of the HSC pool. The relatively mild phenotype in the HSC compartment of the OPN knockout mouse, however, suggests that additional mechanisms function to prevent exhaustion of the HSC pool in the absence of OPN 37 .
Moreover, while it may be necessary to combine multiple cycles of OPN blockade with chemotherapy in order to achieve maximal therapeutic benefit, the temporary nature of the OPN inhibition is likely to make this approach feasible. Alternatively, therapies could be designed to reinforce the interaction between BM OPN and leukemia cells in order to induce quiescence.
Such an approach could be used to enforce a dormant state on leukemia in the BM, thus preventing or slowing disease progression.
In summary, we have demonstrated a unique mechanism by which leukemic blasts hijack a HSC BM niche to gain indirect protection from cytotoxic chemotherapy. These data demonstrate for the first time how BM niches can play a functional role in controlling ALL cell dormancy:
Leukemic cells utilize stromal-derived OPN to anchor themselves in microdomains that support
For personal use only. on April 19, 2017 . by guest www.bloodjournal.org From quiescence. As tumor growth progresses, blasts secrete OPN into the local microenvironment, where it is incorporated into the ECM and may function to reinforce the dormant phenotype.
OPN neutralization may in turn be an effective strategy to reduce blast dormancy and increase the efficacy of currently used cytotoxic chemotherapeutic regimens in human ALL patients.
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